ArticlemBio2022
Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris.
Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Pathogenicity and virulence ofVirulence · 2026Review
- Proteome Remodelling inJournal of fungi (Basel, Switzerland) · 2026Article
- Uncovering actionable trade-offs of antifungal resistance in a yeast pathogen.Molecular systems biology · 2026Article
- Review
- The emerging pathogen Candida auris: host interactions and disease drivers.Journal of biomedical science · 2026Review
- Candida auris skin tropism and antifungal resistance are mediated by carbonic anhydrase Nce103.Nature microbiology · 2026Article
- Omics and Multiomics-Based Diagnostics for Invasive Candidiasis: Toward Precision Medicine.Molecular & cellular proteomics : MCP · 2025Review
- A zinc-chelating cyclic alkyl polyamine compound is efficient and safe in a murine model of multidrug-resistantAntimicrobial agents and chemotherapy · 2025Article
- Octenidine effectively reduces Candida auris colonisation on human skin.Scientific reports · 2025Article
- Phenotypic Impact and Multivariable Assessment of Antifungal Susceptibility inJournal of fungi (Basel, Switzerland) · 2025Article
- Signaling pathways governing the pathobiological features and antifungal drug resistance ofmBio · 2025Review
- RapidmSphere · 2025Article
- The Gcn5 lysine acetyltransferase mediates cell wall remodeling, antifungal drug resistance, and virulence ofmSphere · 2025Article
- Article
- Broad-spectrum antifungal activity of C12/C14 alkyl triphenylphosphonium salts (TPP-CFrontiers in microbiology · 2025Article
- The multidrug-resistantCurrent research in microbial sciences · 2025Review
- ThemBio · 2024Article
- What makesAntimicrobial agents and chemotherapy · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 3 countries.
Funding
Abstract
Candida auris emerged as a human fungal pathogen only during the past decade. Remarkably, C. auris displays high degrees of genomic diversity and phenotypic plasticity, with four major clades causing hospital outbreaks with high mortality and morbidity rates. C. auris can show clinical resistance to all classes of antifungal drugs, including echinocandins that are usually recommended as first-line therapies for invasive candidiasis. Here, we exploit transcriptomics coupled with phenotypic profiling to characterize a set of clinical C. auris isolates displaying pronounced echinocandin resistance (ECN-R). A hot spot mutation in the echinocandin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.